Updated:
Nicoya Lifesciences Inc.
Nicoya Lifesciences Inc. was founded in 2012 in Kitchener, Ontario, by a team led by CEO Ryan Denomme, a mechanical engineer who previously worked at...
Nicoya Lifesciences Inc.
Nicoya Lifesciences Inc. was founded in 2012 in Kitchener, Ontario, by a team led by CEO Ryan Denomme, a mechanical engineer who previously worked at BlackBerry. The company produces surface plasmon resonance (SPR) instruments — tools used to measure biomolecular interactions in real time without labeling. Its flagship product, OpenSPR, is marketed as an affordable benchtop alternative to the sprawling SPR systems from Cytiva (formerly Biacore) and Bruker. Nicoya has secured venture capital from the Business Development Bank of Canada, the Ontario government's Ontario Centres of Excellence program, and private angel investors. Its core technologies include digital SPR, microfluidics, and machine-learning algorithms to interpret binding data. The company targets pharmaceutical R&D labs, academic core facilities, and contract research organizations (CROs) in North America, Europe, and Asia. Nicoya has announced direct sales in Canada, the United States, the United Kingdom, Germany, and Japan. In 2025, it published a white paper claiming that OpenSPR can reduce reagent costs by 70% compared to traditional SPR platforms. The firm employs an estimated 40–60 people, though exact headcount is not publicly confirmed. It operates a single office in Kitchener, with no disclosed philanthropic or separate investment vehicles. Nicoya's structural differentiator is its direct-to-lab sales model for benchtop SPR — a market historically dominated by high-cost, floor-standing systems. The company offers OpenSPR as a capital purchase or via a consumable-revenue subscription model, where sensors and chips generate recurring income. Governance is founder-led with no disclosed succession plan. The firm is not registered as an investment advisor; it does not manage third-party capital.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Kitchener
Corporate office
Kitchener, Ontario, Canada
Sector focus
Frequently asked questions
Who runs investment decisions at Nicoya Lifesciences Inc.?
Nicoya Lifesciences Inc. is not an investment firm. It is a life-sciences instrument company. Capital-allocation decisions are made by its board of directors, led by CEO Ryan Denomme, with guidance from venture investors including the Business Development Bank of Canada (per public record).
What is Nicoya's core product and who buys it?
Nicoya's flagship product is OpenSPR, a benchtop surface plasmon resonance (SPR) instrument used to measure biomolecular interactions in real time. Buyers include pharmaceutical R&D labs, academic core facilities, and contract research organizations (CROs) seeking a lower-cost alternative to larger SPR systems from Cytiva and Bruker (per the firm's communications).
Does Nicoya manage capital for external investors?
No. Nicoya Lifesciences Inc. is an operating company — it designs and sells scientific instruments. It does not operate as a family office, asset manager, or investment advisor. It has raised venture capital from public and private sources but does not manage third-party capital (per public record).
What technology differentiates OpenSPR from competitors?
OpenSPR uses a digital SPR technology that eliminates the need for labeling molecules with fluorescent tags, and the company has integrated machine-learning algorithms to automate data interpretation. Nicoya claims this reduces assay costs by up to 70% compared to legacy SPR systems (per a 2025 company white paper).
Where does Nicoya generate its revenue?
Nicoya generates recurring revenue from consumables — sensor chips and reagents used with OpenSPR — plus one-time instrument sales. The company sells directly in Canada, the United States, the United Kingdom, Germany, and Japan (per the firm's website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: